PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Van Elle and Hargreaves Services post profit rises

Wed, 25th Jan 2023 14:43

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hargreaves Services PLC - Durham, England-based land, property and infrastructure development - In the half year to November 30, pretax profit jumps 80% to GBP18.7 million from GBP10.4 million a year prior. Revenue jumps 53% to GBP116.5 million from GBP76.1 million. Net asset value per share grows 31% to 603 pence from 462p. Lifts dividend by 7.1% to 3.0 pence per share from 2.8p. Expects that financial year 2023 results will be in line with market expectations. Meanwhile, Finance Director John Samuel steps down from his role on July 31. He will be replaced by Stephen Craigen a day later. Craigen has been financial controller at company since 2017.

----------

Van Elle Holdings PLC - Nottinghamshire-based geotechnical engineering contractor - In the six months to October 31, pretax profit climbs 74% to GBP3.3 million from GBP1.9 million a year prior. Revenue increases to GBP80.8 million from GBP60.1 million. Declares an interim dividend of 0.4p per share versus none a year ago. Net debt as at October 31 widens to GBP2.5 million from GBP2.0 million a year prior. Adds that current trading is in line with management's expectations. Says it is confident in achieving market expectations for financial year 2023, which it says are an underlying pretax profit of GBP5.3 million with a range of GBP5.2 million to GBP5.4 million. In August, the company had reported an underlying profit of GBP1.9 million.

----------

IOG PLC - North Sea-focused gas and infrastructure operator - Reports 2022 revenue before sales deductions of GBP79.6 million, compared to nothing in 2021 as 2022 was IOG's first year as producer. Gas output from March to December 31 was 27.4 million standard cubic feet per day. Average realised gas price was 203.5p per therm, which includes short-term price fixes. For January 2023, IOG notes a 319p per therm price fix for 30,000 therms per day is in place. Company aims to release its 2022 results during March. IOG notes that the UK North Sea Transition Authority is expected to make the first 33rd round license awards in the second quarter of 2023.

----------

Scancell Holdings PLC- Nottingham, England-based cancer immunotherapies developer - In the six months to October 31, turns to pretax loss of GBP4.1 million from a profit of GBP2.5 million a year prior. Development expenses widen to GBP4.9 million from GBP4.0 million as administrative expenses widen to GBP2.4 million from GBP1.9 million. Reports finance expense of GBP910,000 relating to revaluation of derivative liability, swung from a gain of GBP2.4 million a year earlier. Does not yet generate revenue. Meanwhile, gives an update on a study on a vaccine trial. 14 patients were enrolled and dosed in expansion phase of the cancer-focused Modi-1 trial, with no safety issues to date. Expands SCIB1 phase 2 combination trial to include doublet therapy, meaning patients will receive two agents, namely skin-cancer focused ipilimumab and nivolumab, which is used to treat several cancers. Says expansion leads to significantly increased recruitment rate. Notes that recruitment for its Covidity clinical trial in South Africa is complete. Expects safety and immunogenicity data from Covidity in the first quarter of 2023.

----------

SuperSeed Capital Ltd - venture capital for early-stage business-to-business technology companies in UK - Says in the fourth quarter of 2022, Fund II portfolio monthly recurring revenue grows 21%. Adds that for 2022, Fund II portfolio monthly recurring revenue rises three-fold. Expects Fund portfolio company revenue to more than double in 2023. "Looking ahead, SuperSeed continues to lean into artificial intelligence as the main tech driver for change. We expect continued strong revenue growth in the portfolio," the company says. Meanwhile, SuperSeed expects that the fund will invest in 5 to 10 more service as a software companies in 2023.

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
19 Feb 2021 12:40

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells 1.3 Million Shares

Read more
17 Feb 2021 16:22

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

IN BRIEF: Scancell Non-Exec Director Diggle Sells GBP95,000 In Shares

Read more
3 Feb 2021 14:53

Scancell ends clinical development partnership with Cancer Research UK

(Sharecast News) - Novel immunotherapy developer Scancell updated the market on its SCIB2 clinical development partnership with Cancer Research UK on Wednesday, reporting that due to the impact of the Covid-19 pandemic and Cancer Research UK's re-evaluation of its collaboration model, the parties had agreed to end their clinical development partnership.

Read more
3 Feb 2021 11:20

CORRECT: AIM WINNERS & LOSERS: Brave Bison Charges Ahead

CORRECT: AIM WINNERS & LOSERS: Brave Bison Charges Ahead

Read more
3 Feb 2021 11:11

AIM WINNERS & LOSERS: Brave Bison Charges Ahead On Contract Win

AIM WINNERS & LOSERS: Brave Bison Charges Ahead On Contract Win

Read more
3 Feb 2021 09:48

Scancell Assessing SCIB2 Options As Cancer Research UK Pact Ends

Scancell Assessing SCIB2 Options As Cancer Research UK Pact Ends

Read more
29 Jan 2021 15:05

IN BRIEF: Scancell Posts Interim Pretax Loss; To Develop Virus Vaccine

IN BRIEF: Scancell Posts Interim Pretax Loss; To Develop Virus Vaccine

Read more
21 Dec 2020 19:39

Oxford Technology VCTs In Mixed Quarter Amid Scancell Rise, Ixaris Hit

Oxford Technology VCTs In Mixed Quarter Amid Scancell Rise, Ixaris Hit

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more
18 Dec 2020 10:26

Scancell Shares Rise As It Chooses Vaccine Candidate For Development

Scancell Shares Rise As It Chooses Vaccine Candidate For Development

Read more
18 Dec 2020 10:17

Scancell selects Covid-19 vaccine candidate for development and trials

(Sharecast News) - Immunotherapy developer Scancell has selected its Covid-19 vaccine candidate 'SN14' for further development and clinical trials, it announced on Friday.

Read more
16 Dec 2020 09:21

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 750,000 Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 750,000 Shares

Read more
14 Dec 2020 16:59

UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares

Read more
25 Nov 2020 16:44

UK DIRECTOR DEALINGS SUMMARY: IG Design Chair Banks GBP1.2 Million

UK DIRECTOR DEALINGS SUMMARY: IG Design Chair Banks GBP1.2 Million

Read more
17 Nov 2020 15:40

UK EXECUTIVE CHANGE SUMMARY: Naked Wines, Tissue Regenix Make US Moves

UK EXECUTIVE CHANGE SUMMARY: Naked Wines, Tissue Regenix Make US Moves

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.